Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees.
Macaca mulatta monkeys were immunized with the candidate transmission-blocking vaccine against Plasmodium vivax, Pvs25, combined with alum or Montanide ISA 720. Efficacy was measured by combining post-immunization sera with gametocytes obtained from infections induced in chimpanzees using membrane-feeding techniques. The results indicate that immunization of M. mulatta monkeys with Pvs25 and Montanide ISA 720 was more effective than with alum in efficacy and resulted in the maintenance of a lasting transmission-blocking immunity to P. vivax. This was evident two weeks after the second immunization, and more strongly demonstrable 62 and 152 days after the second immunization. This transmission-blocking activity was strongly reinforced by a third immunization given 181 days after the primary immunization, as measured three weeks later by indirect membrane feeding. The use of gametocytes of P. vivax derived from infections induced in chimpanzees can contribute to the selection of appropriate constructs, formulations, and immunization regimens for the development of effective transmission-blocking vaccines.
Malaria Branch, Division of Parasitic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
William E
WE
Collins
John W
JW
Barnwell
Joann S
JS
Sullivan
Douglas
D
Nace
Tyrone
T
Williams
Amy
A
Bounngaseng
Jacquelin
J
Roberts
Elizabeth
E
Strobert
Harold
H
McClure
Allan
A
Saul
Carole A
CA
Long
D000534:Alum Compounds; D000818:Animals; D000852:Anopheles; D000953:Antigens, Protozoan; D000954:Antigens, Surface; D005260:Female; D005854:Germ Cells / Q000166:cytology; D008253:Macaca mulatta; D017780:Malaria Vaccines; D016780:Malaria, Vivax / Q000276:immunology / Q000517:prevention & control / Q000635:transmission*; D008297:Male; D008353:Mannitol / Q000031:analogs & derivatives; D009821:Oils; D009829:Oleic Acids; D010966:Plasmodium vivax / Q000276:immunology*; D017778:Vaccines, Combined
D000534:Alum Compounds; D000953:Antigens, Protozoan; D000954:Antigens, Surface; D017780:Malaria Vaccines; D009821:Oils; D009829:Oleic Acids; C121473:Pvs25 protein, P vivax; D017778:Vaccines, Combined; C001681:mannide monooleate; C041524:aluminum sulfate; D008353:Mannitol